Allarity Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
INDEX
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS | ii | |
|---|---|---|
| NOTE | ||
| PART I | 1 | |
| ITEM 1. | BUSINESS | 1 |
| ITEM 1A. | RISK FACTORS | 31 |
| ITEM 1B. | UNRESOLVED STAFF COMMENTS | 73 |
| ITEM 1C. | CYBERSECURITY | 73 |
| ITEM 2. | PROPERTIES | 73 |
| ITEM 3. | LEGAL PROCEEDINGS | 74 |
| ITEM 4. | MINE SAFETY DISCLOSURES | 74 |
| PART II | ||
| ITEM 5. | MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES | 74 |
| ITEM 6. | [RESERVED] | 75 |
| ITEM 7. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 75 |
| ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 85 |
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 85 |
| ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 85 |
| ITEM 9A | CONTROLS AND PROCEDURES | 85 |
| ITEM 9B. | OTHER INFORMATION | 86 |
| ITEM 9C. | DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENTS INSPECTIONS | 86 |
| PART III | 87 | |
| ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 87 |
| ITEM 11. | EXECUTIVE COMPENSATION | 93 |
| ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS | 93 |
| ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE | 93 |
| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES | 93 |
| PART IV | 94 | |
| ITEM 15. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES | 94 |
| SIGNATURES | 98 | |
| FINANCIAL STATEMENTS | F-1 | |
When used herein, unless the context requires otherwise, references to the “Company,” “Allarity,” “we,” “our” and “us” refer to Allarity Therapeutics, Inc., a Delaware corporation. References in this Annual Report to “our therapeutic candidate,” “our therapeutic candidate, stenoparib,” or “stenoparib” refer to our sole current therapeutic candidate, stenoparib, also known as 2X-121 or E7449.
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.